BERGEN,
Norway, Nov. 20, 2024 /PRNewswire/
-- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical needs, announced today the
appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the
position on November 21, 2024.
Mr. Hellebø brings three decades of experience in the
pharmaceutical and biotechnology industries. Since 2023, he has
served as board director in the clinical stage immuno-oncology
company Cytovation ASA, and since 2021 he has been a board director
at the clinical stage biopharmaceutical company, Antev Ltd,
specializing in urology and oncology treatments. Prior to this, Mr.
Hellebø's experience includes the role as CEO of ReNeuron Group
PLC, a UK-based clinical-stage company specializing in cell therapy
for ophthalmic and neurology-related diseases, and CEO at Clavis
Pharma ASA, an oncology-focused biotech company traded at the Oslo
Stock Exchange. Mr Hellebø's earlier career includes
leadership roles at UCB-Celltech, Novartis UK, and at
Schering-Plough (now part of Merck & Co.).
"BerGenBio is at the forefront of exploring highly selective AXL
inhibition as a therapeutic enhancement for the large number of
patients with non-squamous non-small cell lung cancer with
mutations in the STK11 gene. I am thrilled to join the company and
look forward to collaborating with the board and team to advance
the candidate drug, bemcentinib, through the next stages of
clinical development and to take BerGenBio to the next phase", said
Olav Hellebø.
"Mr. Hellebø brings a wealth of experience as a leader in
pharmaceutical and biotechnology companies, with a strong track
record of success. His extensive expertise in leading biotech
companies, raising capital, and securing partnership deals makes
him exceptionally well-suited to guide BerGenBio and to execute on
our focused strategy to study STK11m NSCLC patients in our on-going
Ph1b/2a BGBC016 trial", said Chairman of the Board, Anders Tullgren.
Contacts
Anders Tullgren, Chair of the Board, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio
ASA
rune.skeie@bergenbio.com
Jan Lilleby, Media Relations,
BerGenBio ASA
jl@lillebyfrisch.no
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including cancer
and severe respiratory infections. The Company is focused on its
proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11
mutated NSCLC and severe respiratory infections. BerGenBio is based
in Bergen, Norway with a
subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For
more information, visit www.bergenbio.com
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-appoints-olav-hellebo-as-ceo,c4069475
View original
content:https://www.prnewswire.co.uk/news-releases/bergenbio-appoints-olav-hellebo-as-ceo-302312066.html